Stocks · News reference
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of a Type C
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q2 earnings